基础胰岛素转换德谷胰岛素利拉鲁肽注射液的病例分享  

Case Sharing of Insulin Degludec and Liraglutide Injection(IDegLira)in Patients with Type 2 Diabetes Uncontrolled by Basal Insulin

作　　者：赖亚新[1] 肖新华[2] LAI Yaxin;XIAO Xinhua(The First Hospital of China Medical University,Shenyang Liaoning 110000,China;Peking Union Medical College Hospital,Beijing 100730,China)

机构地区：[1]中国医科大学附属第一医院,辽宁沈阳110000 [2]北京协和医院,北京100730

出　　处：《药品评价》2022年第21期1336-1339,共4页Drug Evaluation

摘　　要：回顾性总结4例因基础胰岛素联合或不联合口服降糖药控制不佳转换为德谷胰岛素利拉鲁肽注射液(IDegLira)联合或不联合口服降糖药的成人2型糖尿病患者病例资料。结果发现,从出院至最长随访3个月期间,患者空腹和餐后血糖均有明显改善,2例体重、腰围明显下降,1例患者出现轻度低血糖反应和胃肠道不良反应,整体有效性和耐受性良好。Retrospective investigation analyzed clinical data of 4 adult patients with type 2 diabetes uncontrolled by basal insulin combined with or without oral hypoglycemic drugs.From hospital discharge to the longest follow-up of 3 months,both fasting and postprandial glucose were improved after switching to Insulin Degludec and Liraglutide Injection(IDegLira)with or without oral antidiabetic drugs.Body weight loss and decrease in abdominal circumference were significantly observed in 2 of 4 patients.Mild hypoglycemia and gastrointestinal adverse effects occurred only in 1 patient.In general,IDegLira was totally effective and well-tolerated with or without oral hypoglycemic drugs in patients uncontrolled by basal insulin.

关 键 词：糖尿病 2型 德谷胰岛素利拉鲁肽注射液 基础胰岛素 

分 类 号：R587.1[医药卫生—内分泌]